Stockscreener 앱 받기
17.14
7.80%
1.24
전일 마감가:
$15.90
열려 있는:
$15.98
하루 거래량:
498.11K
Relative Volume:
0.79
시가총액:
$219.19M
수익:
-
순이익/손실:
$-121.02M
주가수익비율:
-1.5222
EPS:
-11.26
순현금흐름:
$-114.09M
1주 성능:
+10.72%
1개월 성능:
-7.85%
6개월 성능:
-61.96%
1년 성능:
-27.06%
1일 변동 폭
$15.74
$17.30
1주일 범위
$14.97
$17.30
52주 변동 폭
$7.31
$69.97
토닉스 파마슈티컬스 홀딩 Stock (TNXP) Company Profile
명칭
Tonix Pharmaceuticals Holding Corp
전화
212-980-9155
주소
26 MAIN STREET, SUITE 101, CHATHAM, NY
TNXP을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TNXP
Tonix Pharmaceuticals Holding Corp
|
17.14 | 203.33M | 0 | -121.02M | -114.09M | -11.26 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.36 | 111.36B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.04 | 77.98B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
800.01 | 50.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.27 | 47.46B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.19 | 37.43B | 4.98B | 69.59M | 525.67M | 0.5197 |
토닉스 파마슈티컬스 홀딩 Stock (TNXP) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2022-04-18 | 개시 | Noble Capital Markets | Outperform |
| 2019-04-18 | 업그레이드 | ROTH Capital | Neutral → Buy |
| 2017-08-18 | 업그레이드 | ROTH Capital | Neutral → Buy |
| 2016-09-07 | 다운그레이드 | ROTH Capital | Buy → Neutral |
| 2016-02-17 | 재확인 | Oppenheimer | Outperform |
| 2015-11-04 | 개시 | Cantor Fitzgerald | Buy |
| 2015-06-12 | 개시 | Oppenheimer | Outperform |
| 2015-02-17 | 재확인 | ROTH Capital | Buy |
| 2014-09-29 | 재확인 | ROTH Capital | Buy |
모두보기
토닉스 파마슈티컬스 홀딩 주식(TNXP)의 최신 뉴스
How (TNXP) Movements Inform Risk Allocation Models - Stock Traders Daily
Returns Recap: Will Tonix Pharmaceuticals Holding Corp stock benefit from M A2025 Major Catalysts & Advanced Swing Trade Entry Plans - baoquankhu1.vn
Market Fear: Can Tonix Pharmaceuticals Holding Corp stock outperform in a bear market2025 Top Decliners & Comprehensive Market Scan Reports - baoquankhu1.vn
Tonix Pharmaceuticals (NASDAQ:TNXP) Upgraded by Wall Street Zen to Hold Rating - MarketBeat
Aug PostEarnings: What are Tonix Pharmaceuticals Holding Corps earnings expectationsWeekly Volume Report & Detailed Earnings Play Strategies - baoquankhu1.vn
Analyst Downgrade: Will Tonix Pharmaceuticals Holding Corp face regulatory challengesJuly 2025 Momentum & Technical Confirmation Alerts - baoquankhu1.vn
Fibromyalgia Market Insights Highlight Expanding Outlook Till 2034, DelveInsight Evaluates - openPR.com
Block Trades: What is the fair value of Tonix Pharmaceuticals Holding Corp. stock now2025 Key Highlights & Reliable Intraday Trade Plans - moha.gov.vn
How rising interest rates impact Tonix Pharmaceuticals Holding Corp. stockBreakout Watch & Verified Momentum Watchlists - Улправда
Take Profit: How analysts rate Tonix Pharmaceuticals Holding Corp. stock todayWeekly Market Outlook & Long Hold Capital Preservation Plans - Улправда
Will Tonix Pharmaceuticals Holding Corp. stock see insider buyingWatch List & Stepwise Swing Trade Plans - Улправда
Can Tonix Pharmaceuticals Holding Corp. stock withstand economic slowdownJuly 2025 Volume & Long Hold Capital Preservation Tips - ulpravda.ru
How analysts rate Tonix Pharmaceuticals Holding Corp. stock today2025 Key Highlights & Trade Opportunity Analysis - ulpravda.ru
Trading Systems Reacting to (TNXP) Volatility - Stock Traders Daily
Daily News - FinancialContent
Tonix Pharmaceuticals to Present at Two Investor Conferences in January 2026 - The Manila Times
About Us - FinancialContent
Tonix highlights pathway for potential single-dose, seasonal protection against Lyme Disease - Proactive financial news
Tonix Pharmaceuticals to meet with FDA in 2026 to advance experimental Lyme disease prevention drug - MSN
Tonix Pharmaceuticals (NASDAQ:TNXP) Cut to "Sell" at Wall Street Zen - MarketBeat
Tonix Pharmaceuticals Shares Climb on Encouraging TNX-801 Vaccine Results - MSN
Aug Gainers: How Tonix Pharmaceuticals Holding Corp stock reacts to inflationary pressuresMarket Activity Recap & Weekly Watchlist for Hot Stocks - moha.gov.vn
Tonix prices 615,025 shares at $16.26 in registered direct offering - Yahoo Finance
Tonix Pharma announces $20 million registered direct offering - MSN
Tonix Pharmaceuticals advances TNX-4800 for Lyme disease prevention By Investing.com - Investing.com Nigeria
Tonix Pharmaceuticals secures $20 million investment from Point72 By Investing.com - Investing.com Nigeria
Tonix Pharma advances TNX-4800 Lyme disease program - MSN
Tonix Pharma Announces $20 Million Registered Direct Offering - TipRanks
Form 424B5 Tonix Pharmaceuticals - StreetInsider
Tonix Pharmaceuticals To Meet With FDA In 2026 To Advance Experimental Lyme Disease Prevention Drug - Asianet Newsable
What's Going On With Tonix Pharma Stock Monday?Tonix Pharmaceuticals (NASDAQ:TNXP) - Benzinga
Tonix Pharmaceuticals (TNXP) Secures $20 Million Investment - GuruFocus
Tonix Pharmaceuticals (TNXP) Unveils Updates on Lyme Disease Tre - GuruFocus
Tonix Pharmaceuticals Prices $20 Million Registered Direct Offering - marketscreener.com
Tonix Pharmaceuticals shares fall 6.4% premarket after co prices stock and warrant offering - marketscreener.com
Tonix Pharmaceuticals advances TNX-4800 for Lyme disease prevention - Investing.com
Tonix Pharmaceuticals Announces Pricing of $20.0 Million Registered Direct Offering - GlobeNewswire
Drugmaker behind new fibromyalgia drug raises $20M for pipeline - Stock Titan
Tonix Pharmaceuticals Announces Updates on TNX-4800 for Lyme Disease Prevention - TradingView — Track All Markets
Tonix Pharmaceuticals Advances TNX-4800 Development for Lyme Disease Prevention Planning Clinical Trials for Innovative Monoclonal Antibody Therapy - Quiver Quantitative
Tonix Unveils Once-Yearly Lyme Prevention Antibody, Eyes FDA Talks In 2026 - Sahm
Avoiding Lag: Real-Time Signals in (TNXP) Movement - Stock Traders Daily
TNXP (Tonix Pharmaceuticals Holding) Forward Rate of Return (Yacktman) % : 0.00% (As of Sep. 2025) - GuruFocus
Tonix licenses global rights to novel non-opioid neuropathic pain drug TNX-4900 - Proactive financial news
Noble Financial Has Positive Outlook of TNXP FY2025 Earnings - MarketBeat
Published on: 2025-12-22 01:46:59 - Улправда
How Tonix Pharmaceuticals Holding Corp. stock benefits from tech adoptionJuly 2025 Summary & Low Risk Growth Stock Ideas - DonanımHaber
How Tonix Pharmaceuticals Holding Corp. stock reacts to inflationary pressuresMarket Growth Report & Verified Momentum Stock Watchlist - DonanımHaber
Why Tonix Pharmaceuticals Holding Corp. stock is trending among retail tradersAnalyst Upgrade & Safe Entry Trade Reports - Улправда
Tonix licenses S1R antagonist from Rutgers University - BioWorld MedTech
Tonix Pharma secures rights to TNX-4900 for pain management - MSN
토닉스 파마슈티컬스 홀딩 (TNXP) 재무 분석
매출
순이익
현금흐름
주당 순 이익
4.73%
0.92%
자본화:
|
볼륨(24시간):